ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2541

Differential Responses to Initial Treatment Strategies for Rheumatoid Arthritis Among Those with Lower Body Mass and Adiposity

Joshua Baker1, James O'Dell2, Bryant England2, Jon Giles3, Jefferey Newcomb4, Michael George1, Geoffrey Thiele2, Larry Moreland5, S. Louis Bridges6, Jeffrey R Curtis7 and Ted R Mikuls8, 1University of Pennsylvania, Philadelphia, PA, 2University of Nebraska Medical Center, Omaha, NE, 3Columbia University, New York, NY, 4University of Nebraska, Omaha, NE, 5University of Colorado, Denver, CO, 6Hospital for Special Surgery, New York, NY, 7Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, 8Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

Meeting: ACR Convergence 2023

Keywords: body mass, Disease Activity, rheumatoid arthritis, Tumor necrosis factor (TNF)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: Abstracts: RA – Treatments III: Predictors of Response & Tapering

Session Type: Abstract Session

Session Time: 4:00PM-5:30PM

Background/Purpose: The identification of measures that help predict who is likely to benefit most from early escalation to biologic therapy would inform personalized care among patients with rheumatoid arthritis (RA) early in the course of the disease. While prior studies have assessed how body mass index (BMI) and adiposity might influence responses to therapy, these studies rarely have compared two active treatment strategies. We aimed to determine if BMI and circulating adipokines (peptide hormones produced by adipose tissue) can identify patients most likely to benefit from early initiation of tumor necrosis factor inhibitors (TNFi) as initial therapy compared to combination therapy with conventional DMARDs.

Methods: This is a secondary analysis of the Rheumatoid Arthritis Comparison of Active Treatments (RACAT) trial and the Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) trial. Both trials evaluated strategies with conventional DMARDs (triple therapy) compared to strategies that included TNFi (etanercept), among patients with active RA. We compared response rates between TNFi and triple therapy among patients with different BMI (normal/underweight v. overweight/obese). Adipokines were also measured at enrollment in RACAT using validated assays and we explored the association between an adipokine score (number of adipokines above/below the median, grouping those that directionally reflect greater adiposity) and response within the two treatment arms. Analyses were adjusted for age, sex, BMI, and baseline disease activity (DAS28).

Results: We included 306 participants that were eligible from RACAT and 601 from TEAR. In RACAT, greater change in DAS28 and greater ACR20 response was observed for TNFi initiators compared to triple therapy among participants that were normal or underweight (ACR 20: 64% v. 23%) while no differences between TNFi and triple therapy were observed among overweight and obese (p for interaction = 0.001) (Table). Similar patterns were observed in TEAR, though were more modest. The pattern in TEAR was similar among methotrexate-naïve initiators at baseline and methotrexate inadequate responders at 6-months (combined data are shown in Table). In RACAT, adipokine scores below the median (< 2) and a profile consistent with lower adiposity were associated with greater response to TNFi (ACR20: 58% v. 37%) (Figure). The addition of adipokines to the model resulted in better model fit compared to a model with BMI alone (p=0.01).

Conclusion: Low BMI and evidence of low adiposity based on adipokine profiles are both associated with a superior response to initiation of TNFi compared to the initiation of triple therapy. This is the first study, to our knowledge, to identify a meaningful difference between two active strategies based on weight and body habitus and may reflect phenotypic differences or pharmacodynamic effects. The results support earlier escalation to TNFi among thin patients that do not respond to methotrexate and have implications for future clinical trial design.

Supporting image 1

Table 1: Changes in RA outcomes at 24 weeks by BMI and treatment from regression models, adjusted for age, sex, and baseline DAS28.

Supporting image 2

Figure 1: American College of Rheumatology Response rates in RACAT among 1) participants with a low adipokine score receiving triple therapy (blue solid bar); 2) participants with a low adipokine score receiving immediate etanercept (blue striped bar); 3) participants with a high adipokine score receiving triple therapy (red solid bar), and 4) participants with a high adipokine score receiving etanercept (red striped bar).


Disclosures: J. Baker: Bristol-Myers Squibb(BMS), 2, Burns-White, LLC, 2, CorEvitas, LLC, 2, Pfizer, 2; J. O'Dell: None; B. England: Boehringer-Ingelheim, 2, 5; J. Giles: AbbVie, 2, Eli Lilly, 2, Gilead, 2, Novartis, 2, Pfizer, 2; J. Newcomb: None; M. George: AbbVie/Abbott, 2, GlaxoSmithKlein(GSK), 5, Janssen, 5; G. Thiele: None; L. Moreland: Boehringer-Ingelheim, 12, member of independent Data Safety Monitoring Board, Celltrion, 12, member of independent Data Safety Monitoring Board; S. Bridges: None; J. Curtis: AbbVie, 2, 5, Amgen, 2, 5, BMS, 2, 5, Corrona, 2, 5, Crescendo, 2, 5, Genentech, 2, 5, Janssen, 2, 5, Pfizer, 2, 5, Roche, 2, 5, UCB Pharma, 2, 5; T. Mikuls: Elsevier, 9, Horizon Therapeutics, 2, 5, Pfizer, 2, Sanofi, 2, UCB Pharma, 2, Wolters Kluwer Health (UpToDate), 9.

To cite this abstract in AMA style:

Baker J, O'Dell J, England B, Giles J, Newcomb J, George M, Thiele G, Moreland L, Bridges S, Curtis J, Mikuls T. Differential Responses to Initial Treatment Strategies for Rheumatoid Arthritis Among Those with Lower Body Mass and Adiposity [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/differential-responses-to-initial-treatment-strategies-for-rheumatoid-arthritis-among-those-with-lower-body-mass-and-adiposity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differential-responses-to-initial-treatment-strategies-for-rheumatoid-arthritis-among-those-with-lower-body-mass-and-adiposity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology